ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO090

The Influence of Hypophosphatemia on Outcomes during CRRT in AKI Patients

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational

Authors

  • Jung, Yeonsoon, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Lee, Weon hyung, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Shin, Ho Sik, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Rim, Hark, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Kim, Hyo jong, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
  • Kim, Ye na, Kosin University College of Medicine, Gospel Hospital, Busan, Korea (the Republic of)
Background

To assess the role of hypophosphatemia in major clinical outcomes in patients treated with low-or high-intensity continuous renal replacement therapy(CRRT).

Methods

We performed a retrospective analysis of data collected from 620 patients. We divided the patients into two different groups of CRRT intensity (more than or less than 40 mL/kg/hour of effluent generation) and measured serum phosphate level daily.

Results

We obtained a total of 1800 phosphate measurements on days 0,1 and 2 and identified 49 patients (8%), 93 patients (15%), and 142 patients (23%) with hypophosphatemia on each of these respective days. In patients treated with lower-intensity CRRT, 23 episodes of hypophosphatemia/1000 patinet days were identified, compared with 83 episodes/1000 patient days in patients receiving higher-intensity CRRT (P < 0.01). Multiple Cox proportional hazards analyses showed that APACHE score, utilization of vasoactive drugs, and arterial pH on the third CRRT day were significant predictors of mortality; however, serum phosphate level was not a sinificant contributor.

Conclusion

The APACHE score, use of vasoactive drugs, and arterial pH on the 2nd CRRT day were significant predictors of mortality. Hypophosphatemia might not eb a major risk factor of increased motality in patients treate with CRRT.